Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac
Open Access
- 1 August 2006
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (8) , 4557-4565
- https://doi.org/10.1128/iai.00466-06
Abstract
The prediction of efficacy of Neisseria meningitidis serogroup B (MenB) vaccines is currently hindered due to the lack of an appropriate correlate of protection. For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined by the serum bactericidal antibody (SBA) assay and OMV enzyme-linked immunosorbent assay (ELISA). However, the opsonophagocytic assay (OPA), surface labeling assay, whole blood assay (WBA), and salivary antibody ELISA have been developed although correlation with protection is presently undetermined. Therefore, the aim of the study was to investigate further the usefulness of, and relationships between, MenB immunologic assays. A phase II trial of the OMV vaccine, MenBvac, with proven efficacy was initiated to compare immunologic assays incorporating the vaccine and six heterologous strains. Correlations were achieved between the SBA assay, OMV ELISA, and OPA using human polymorphonuclear leukocytes and human complement but not between an OPA using HL60 phagocytic cells and baby rabbit complement. Correlations between the surface labeling assay, the SBA assay, and the OMV ELISA were promising, although target strain dependent. Correlations between the salivary antibody ELISA and other assays were poor. Correlations to the WBA were prevented since many samples had results greater than the range of the assay. The study confirmed the immunogenicity and benefit of a third dose of MenBvac against the homologous vaccine strain using a variety of immunologic assays. These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease.Keywords
This publication has 38 references indexed in Scilit:
- Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2005
- From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal diseaseVaccine, 2005
- Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trialsVaccine, 2005
- Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school childrenVaccine, 2004
- Antibody Specificities and Effect of Meningococcal Carriage in Icelandic Teenagers Receiving the Norwegian Serogroup B Outer Membrane Vesicle VaccineInfection and Immunity, 2003
- Cross-Reactivity of Antibodies against PorA after Vaccination with a Meningococcal B Outer Membrane Vesicle VaccineInfection and Immunity, 2003
- Bactericidal antibody response toNeisseria meningitidisserogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccineFEMS Immunology & Medical Microbiology, 2000
- Concurrent Measurement of Antigen- and Antibody-Dependent Oxidative Burst and Phagocytosis in Monocytes and NeutrophilsMethods, 2000
- Neutrophil Response toNeisseria meningitidis:Inhibition of Adhesion Molecule Expression and Phagocytosis by Recombinant Bactericidal/Permeability‐Increasing Protein (rBPI21)The Journal of Infectious Diseases, 1999
- Killing of Meningococci by Neutrophils: Effect of Vaccination on Patients with Complement DeficiencyThe Journal of Infectious Diseases, 1994